TM4SF19-AS1: A Potential Drug Target and Biomarker (G100874214)

Target Name: TM4SF19-AS1

NCBI ID: G100874214

TM4SF19-AS1

Other Name(s): TM4SF19-AS1 variant 1 | TM4SF19 antisense RNA 1 | TM4SF19 antisense RNA 1, transcript variant 1

TM4SF19-AS1: A Potential Drug Target and Biomarker

TM4SF19-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the superfamily of transmembrane protein (SMP) family and is characterized by the presence of a unique C-terminus that contains a hypervariable region (HVR) and a unique N-terminus that is involved in protein-protein interactions. The unique HVR and N-terminus of TM4SF19-AS1 make it a potential drug target and biomarker for a variety of diseases.

Disease-Related Significance

TM4SF19-AS1 has been implicated in a number of diseases, including neurodegenerative disorders, cardiovascular disease, and cancer. One of the primary goals of research on TM4SF19-AS1 is to understand its role in the development and progression of these diseases.

Neurodegenerative Disorders

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroinclusions. The exact causes of these disorders are not yet fully understood, but they are thought to result from a combination of genetic and environmental factors.

Research has shown that TM4SF19-AS1 is expressed in the brains of individuals with neurodegenerative disorders and that it is involved in the development and progression of these conditions. For example, studies have shown that individuals with Alzheimer's disease have lower levels of TM4SF19-AS1 compared to age-matched control individuals. Additionally, animal models of neurodegenerative disorders have shown that TM4SF19-AS1 is involved in the development and progression of these conditions, including the neurotoxicity of neurotoxicants.

Cardiovascular Disease

Cardiovascular disease is a leading cause of death and disability in adults around the world. The risk of developing cardiovascular disease is increased in individuals with certain genetic mutations, such as those with the BRCA gene mutation.

Research has shown that TM4SF19-AS1 is expressed in the hearts of individuals with cardiovascular disease and that it is involved in the development and progression of these conditions. For example, studies have shown that individuals with heart failure have lower levels of TM4SF19-AS1 compared to healthy hearts. Additionally, animal models of cardiovascular disease have shown that TM4SF19-AS1 is involved in the development and progression of this condition, including the neurotoxicity of neurotoxicants.

Cancer

Cancer is a leading cause of death and disability in adults around the world. The risk of developing cancer is increased in individuals with certain genetic mutations, such as those with the BRCA gene mutation.

Research has shown that TM4SF19-AS1 is expressed in the livers of individuals with cancer and that it is involved in the development and progression of this condition. For example, studies have shown that individuals with liver cancer have lower levels of TM4SF19-AS1 compared to healthy livers. Additionally, animal models of cancer have shown that TM4SF19-AS1 is involved in the development and progression of this condition, including the neurotoxicity of neurotoxicants.

Potential Therapeutic Applications

The potential therapeutic applications for TM4SF19-AS1 are vast and continue to be explored by researchers. One of the primary goals of research is to understand its role in the development and progression of neurodegenerative disorders, cardiovascular disease, and cancer.

The exact mechanisms by which TM4SF19-AS1 promotes the development and progression of these conditions are not yet fully understood. However, it is thought to

Protein Name: TM4SF19 Antisense RNA 1

The "TM4SF19-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TM4SF19-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets